title: Synergistic anti-tumor actions of luteolin and silibinin prevented cell migration and invasion and induced apoptosis in glioblastoma SNB19 cells and glioblastoma stem cells.
abstract: Glioblastoma is the most lethal brain tumor. Failure of conventional chemotherapies prompted the search for natural compounds for treatment of glioblastoma. Plant-derived flavonoids could be alternative medicine for inhibiting not only glioblastoma cells but also glioblastoma stem cells (GSC). Two plant-derived flavonoids are luteolin (LUT) and silibinin (SIL). We investigated anti-tumor mechanisms of LUT and SIL in different human glioblastoma cells and GSC and found significant synergistic inhibition of human glioblastoma LN18 and SNB19 cells and GSC following treatment with combination of 20µM LUT and 50µM SIL. Combination of 20µM LUT and 50µM SIL was more effective than a conventional chemotherapeutic agent (BCNU or TMZ). We continued our studies with SNB19 cells and GSC and found dramatic inhibition of cell migration from spheroids and also cell invasion through matrigel following treatment with combination of LUT and SIL. This combination was highly effective to block angiogenesis and survival pathways leading to induction of apoptosis. Inhibition of PKCα, XIAP, and iNOS ultimately caused induction of extrinsic and intrinsic pathways of apoptosis. Collectively, synergistic efficacy of LUT and SIL could be a promising therapy to inhibit cell migration and invasion and induce apoptosis in different glioblastoma cells including GSC.
authors.affiliation: University of South Carolina School of Medicine, Department of Pathology, Microbiology, and Immunology, Columbia, SC 29209, USA.
authors.forename: Mrinmay
authors.initials: M
authors.lastname: Chakrabarti
authors.affiliation: University of South Carolina School of Medicine, Department of Pathology, Microbiology, and Immunology, Columbia, SC 29209, USA. Electronic address: swapan.ray@uscmed.sc.edu.
authors.forename: Swapan K
authors.initials: SK
authors.lastname: Ray
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D001932:Brain Neoplasms / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005909:Glioblastoma / Q000473:pathology; D006801:Humans; D047311:Luteolin / Q000008:administration & dosage*; D009361:Neoplasm Invasiveness / Q000473:pathology / Q000517:prevention & control; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D000077385:Silybin; D012838:Silymarin / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D012838:Silymarin; D000077385:Silybin; D047311:Luteolin
keywords: Apoptosis; Cell migration; Glioblastoma stem cells; Luteolin; SNB19; Silibinin